Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711683.4Aexternal-prioritypatent/GB9711683D0/en
Priority claimed from GBGB9712851.6Aexternal-prioritypatent/GB9712851D0/en
Application filed by Smithkline Beecham PfiledCriticalSmithkline Beecham P
Publication of NZ510672ApublicationCriticalpatent/NZ510672A/en
A process for the preparation of a pharmaceutical composition that comprises 5-[4-[2-(N-methyl-N- (2-pyridyl) amino) ethoxy ] - benzyl ] thiazolidine-2, 4-dione (compound I) involving the following steps: preparing a first composition of compound I in the range of 5 to 20 % weight and a first pharmaceutical carrier; then admixing the first composition with a second pharmaceutical carrier.
Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical, process for its preparation and its pharmaceutical use